Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia

Parkinson Disease Clinical Trial

Official title:

Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A Inhibitor) in Patients With Parkinson's Disease Suffering From Levodopa Induced Dyskinesia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05297201
• Other study ID #: 03PDE2020
• Status: Recruiting
• Phase: Phase 2
• Start date: November 2, 2021
• Est. completion date: December 2024

Study information

• Verified date: February 2024
• Source: Celon Pharma SA
• Contact: CROS CRO Sp. z o. o.
• Phone: +48 796 197 603
• Email: info[@]cros-cro.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia. The study is to determine the efficacy and dose response of two CPL500036 doses, compared with placebo.

Description:

This is a double-blind, randomized, placebo-controlled, parallel-group, dose ranging study, to explore the efficacy, safety, tolerability and pharmacokinetic (PK) of low and high dose of CPL500036 an phosphodiesterase 10A (PDE10A) inhibitor in Parkinson's disease patients with levodopa induced dyskinesia (LID) when administered for 28 days. The study will be conducted at multiple Clinical Sites. Approximately 108 patients will be randomized at 1:1:1 ratio to receive low or high dose of CPL500036 or placebo in a blinded manner, once daily for 28 days (Day 1 to Day 28). The study will comprise of Screening, Baseline (a 4-day in-house period), a Treatment Period and a Follow-Up Period. The patients will be discharged from clinical units during the Treatment Period. Approximately 30% of the patients (11 patients in each of the 3 treatment groups) will undergo extensive PK blood sampling during the Treatment Period and the remaining 70% of the patients will undergo sparse PK blood sampling. Patients from extensive PK blood sampling will be discharged from the Clinical Site on Day 8 and Day 1 for patients from sparse PK blood sampling group respectively.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 108
• Est. completion date: December 2024
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 80 Years

Eligibility

Inclusion criteria:

1. Signed and dated written informed consent.

2. Male or female patient aged between 50 and 80, diagnosed of idiopathic Parkinson's disease according to the United Kingdom Parkinson's Disease Society Brain Bank Clinical Diagnosis Criteria.

3. The patient is on stable dose of Levodopa.

4. Other anti-PD medications are allowed if dosing is optimized and stably used.

5. The patient is has been treated with Levodopa and is suffering from temporally predictable peak-dose LID.

6. Patient declare that dyskinesia is problematic or disabling.

7. Score of dyskinesia is at least 2 on part IV, item 4.2 (of the MDS-UPDRS at Screening and on Day -1).

8. Patient with Hoehn-Yahr stages 2 to 4 (in OFF stage).

9. Female patient is not pregnant (at Screening and Day -1), not breastfeeding and at least 1 of the following conditions applies: (i) woman of non-childbearing potential; (ii) woman of childbearing potential, using contraceptive methods during the Treatment Period and for at least 28 days after the last dose of the study drug. The following are acceptable contraceptive methods: bilateral tubal occlusion, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices and copper intrauterine devices, male or female condom with spermicide; and cap, diaphragm or sponge with spermicide.

10. Male patient must agree to use a barrier method of contraceptive for at least 90 days after the last dose of the study drug.

11. Patient agrees to blood sample collection for DNA analysis.

Exclusion criteria:

1. The patient has (suspected) atypical Parkinson's disease.

2. The patient has a history of neurosurgical intervention because of Parkinson's disease.

3. Patient has unstable medical status which may impact the ability of the patients to participate or potentially confound the study result.

4. Patient has a history of psychotic event induced by anti-PD treatments or impulse control disorder.

5. The patient has any moderate or severe neuromuscular, locomotor disease, that interfere with the study scoring.

6. The Patient has a history of severe head injury, stroke or any diagnosis of significant nervous system disease.

7. Patient has a history of substance abuse or alcohol abuse within 12 months prior to Screening.

8. The patient is pregnant or lactating or intending to become pregnant or intending to donate ova.

9. Patient has a history of neuroleptic malignant syndrome, or known personality disorder, or other psychiatric disorder that, in the opinion of the Investigator, would interfere with participation in the study.

10. Patient with the presence of cognitive impairment evidenced by a Mini-Mental State Exam (MMSE) of less than 19.

11. Patients is considered by the Investigator to be at imminent risk of suicide or injury to self or others.

12. Patients has any existing or previous history of cancer or has newly diagnosed diabetes.

13. Patient has abnormal ECG that, in the opinion of the Investigator, increases the risks associated with participating in the study.

14. Patient has abnormal QT interval, history of unexplained syncope or known family history of sudden death due to QT abnormality.

15. The patient has any laboratory values outside the normal range that are considered by Investigator to be clinically significant at Screening.

16. Patient participated in another interventional clinical study with an IMP

Related Conditions & MeSH terms

• Dyskinesia, Drug-Induced
• Dyskinesia, Medication-Induced
• Dyskinesias
• Parkinson Disease

Intervention

Drug:
• CPL500036 - low dose
CPL500036 will be given orally. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
• CPL500036 - high dose
CPL500036 will be given orally. Each patient is to take 4 capsules with active substance daily.
• Placebo
Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.

Locations

Country	Name	City	State
Poland	Samodzielny Publiczny Szpital Kliniczny nr 4	Lublin	Lubelskie
Poland	Instytut Zdrowia dr Boczarska-Jedynak Sp. Z o.o., Sp. K.,	Oswiecim	Malopolska
Poland	Instytut Psychiatrii i Neurologii	Warszawa	Mazowieckie
Poland	Mazowiecki Szpital Bródnowski	Warszawa	Mazowieckie
Ukraine	Ukrainian State Research Institute of Medical and Social Problems of Disability of the Ministry of Health of Ukraine, Department of Neurology and Borderline Conditions;	Dnipro
Ukraine	Treatment and Diagnostic Centre "Neuro Global" of the Limited Liability Company "Neuro Global", Treatment and Prevention Sub-division	Ivano-Frankivsk
Ukraine	Institute of Neurology, Psychiatry and Narcology of the Academy of Medical Sciences of Ukraine, Department of Vascular Pathology of the Brain and Rehabilitation	Kharkiv
Ukraine	Municipal non-profit enterprise of Lviv regional council "Lviv regional clinical hospital", Neurological Department	Lviv
Ukraine	Limited Liability Company, Medical Center "DIAMED"	Uzhgorod
Ukraine	"INET-09" LLC (Medical Center)	Zaporizhzhia
Ukraine	Educational and Scientific Medical Center "University Clinic" of Zaporizhzhia State Medical University	Zaporizhzhia
Ukraine	Communal Enterprise "Hospital" of Zhytomyr City Council	Zhytomyr

Sponsors (2)

Lead Sponsor	Collaborator
Celon Pharma SA	National Center for Research and Development, Poland

Countries where clinical trial is conducted

Poland,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in total UDysRS score at Week 4.	Determination of the effect of low and high dose of CPL500036 compared to placebo, on the reduction of dyskinesia based on Unified Dyskinesia Rating Scale (UDysRS). The UDysRR scale is used to measure dyskinesia in Parkinson disease. Within a single scale, rater is to evaluate patient perceptions, time factors, anatomical distribution, objective impairment, severity, and disability which are accordingly divided into Part 1, Part 2, Part 3 and Part 4 of the UDysRS scale, respectively.	Day -1, Day 28
Secondary	Change from baseline in UDysRS objective sub-scale scores Part 3 and 4.	Determination of the effect of low and high dose of CPL500036 compared to placebo, on the reduction of dyskinesia based on Unified Dyskinesia Rating Scale (UDysRS). The UDysRR scale is used to measure dyskinesia in Parkinson disease. Within a single scale, rater is to evaluate patient perceptions, time factors, anatomical distribution, objective impairment, severity, and disability which are accordingly divided into Part 1, Part 2, Part 3 and Part 4 of the UDysRS scale, respectively.	Day -1, Week 1, 2, 3 and 4
Secondary	Change from baseline in MDS-UPDRS total score at Week 4	Determination of the effect of low and high dose of CPL500036 compared to placebo using Movement Disorders Society (MDS) Modified Unified Parkinson's Disease Rating Scale (MDS-UPDRS). MDS-UPDRS is use to measure the severity and progression of Parkinson disease (PD). The MDS-UPDRS scale contain 4 parts that captures essential features of Parkinson's disease. Within a single scale, rater is to evaluate non-motor (Part 1) and motor (Part 2) experience of daily living, motor examination (Part III) and motor complications (Part IV).	Day -1, Day 28
Secondary	Change from baseline in MDS-UPDRS Part 4/A scores at Week 4	Determination of the effect of low and high dose of CPL500036 compared to placebo using Movement Disorders Society (MDS) Modified Unified Parkinson's Disease Rating Scale (MDS-UPDRS). MDS-UPDRS is use to measure the severity and progression of Parkinson disease (PD). The MDS-UPDRS scale contain 4 parts that captures essential features of Parkinson's disease. Within a single scale, rater is to evaluate non-motor (Part 1) and motor (Part 2) experience of daily living, motor examination (Part III) and motor complications (Part IV).	Day -1, Day 28
Secondary	Change from baseline in Hauser Subject Diary data in ON time with and without dyskinesia or with non-troublesome dyskinesia.	The Hauser Diary is use to monitor motor fluctuation. Patients are asked to characterize their prevailing motor states in 30-minute intervals.	up to 6 weeks
Secondary	Adverse events assessment	Number of all of adverse events will be assessed.	up to 6 weeks
Secondary	Cmax - maximum CPL500036 plasma concentration	The maximum concentration of the CPL500036 compound in plasma after IMP administration, obtained directly from the measured concentrations.	up to 24 hours post administration on Day 1 and Day 7
Secondary	Tmax - time to reach maximum CPL500036 concentration	The Tmax is time to reach the maximum plasma concentration (Cmax), obtained directly from the actual sampling times.	up to 24 hours post administration on Day 1 and Day 7
Secondary	AUC(0-24) - area under the plasma concentration - time curve from time 0 to 24 hours after IMP administration for CPL500036	The AUC(0-24) is a measure of total plasma exposure to the drug from time point zero to 24 hours after IMP administration.	up to 24 hours post administration on Day 1 and Day 7
Secondary	AUC(0-inf) - area under the plasma concentration - time curve from time 0 to infinity time for CPL500036	The AUC(0-inf) is a measure of total plasma exposure to the drug from time point zero extrapolated to infinity.	up to 24 hours post administration on Day 1 and Day 7
Secondary	Kel - terminal elimination rate constant	Kel is to be estimated via linear regression of time versus log of concentration.	up to 24 hours post administration on Day 1 and Day 7
Secondary	Apparent terminal elimination half-life (T1/2) for CPL500036 compound	T1/2 is to be calculated as 0.693/Kel.	up to 24 hours post administration on Day 1 and Day 7
Secondary	Apparent clearance (CL/F) for CPL500036 compound	Apparent clearance is to be calculated as Dose/AUC(inf)	up to 24 hours post administration on Day 1 and Day 7
Secondary	Apparent volume of distribution during the terminal phase (Vz/F) for CPL500036 compound	Apparent volume of distribution is to be calculated as (CL/F)/ Kel	up to 24 hours post administration on Day 1 and Day 7
Secondary	C(trough) - CPL500036 concentration before dosing	The concentration of CPL500036 on day before product administration.	Day 1 and Day 7
Secondary	Change from baseline in inflammatory cytokines level at Week 4	Determination of the effect of low and high dose of CPL500036 compared to placebo, on the change in concentration of inflammatory cytokines in blood.	Day 1, Day 28
Secondary	Number of abnormal clinically significant findings (physical, neurological, ophthalmological and dermatological examinations).		Up to 6 weeks
Secondary	Number of abnormal clinically significant findings in clinical laboratory assessments (hematology, coagulation, clinical chemistry, urinalysis).		Up to 6 weeks
Secondary	Number of abnormal clinically significant findings in electrocardiogram results.	The following electrocardiogram parameters will be assess: PR interval, QRS interval, RR interval, QT interval and QTc interval.	Up to 6 weeks
Secondary	Number of abnormal clinically significant findings in vital signs assessments (respiratory, body temperature, blood pressure, pulse).		Up to 6 weeks